Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy

Dwayne Boyers; Moira Cruickshank; Neil Scott; Elisabet Jacobsen; Sachin Kumar; Mari Imamura; Paul Manson; Gavin Preston; Miriam Brazzelli

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy

Dwayne Boyers, Moira Cruickshank, Neil Scott, Elisabet Jacobsen, Sachin Kumar, Mari Imamura, Paul Manson, Gavin Preston, Miriam Brazzelli^* (Corresponding Author)

^*Corresponding author for this work

NHS Grampian

Research output: Book/Report › Commissioned Report

Abstract

Evidence Review Group report in support of NICE STA Programme.

Original language	English
Place of Publication	London
Publisher	Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence
Number of pages	128
Publication status	Published - 20 Jun 2022

Bibliographical note

Source of funding: This report was commissioned by the NIHR Systematic Reviews Programme as project number 135560.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://njl-admin.nihr.ac.uk/document/download/2041672Licence: Unspecified

Cite this

Boyers, D., Cruickshank, M., Scott, N., Jacobsen, E., Kumar, S., Imamura, M., Manson, P., Preston, G., & Brazzelli, M. (2022). Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy. Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence. https://njl-admin.nihr.ac.uk/document/download/2041672

Boyers, D , Cruickshank, M , Scott, N , Jacobsen, E, Kumar, S, Imamura, M, Manson, P, Preston, G & Brazzelli, M 2022, Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy. Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence, London. <https://njl-admin.nihr.ac.uk/document/download/2041672>

@book{a0e2ffc1b2024211b5a2244b7c4b21c4,

title = "Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy",

abstract = "Evidence Review Group report in support of NICE STA Programme.",

author = "Dwayne Boyers and Moira Cruickshank and Neil Scott and Elisabet Jacobsen and Sachin Kumar and Mari Imamura and Paul Manson and Gavin Preston and Miriam Brazzelli",

note = "Source of funding: This report was commissioned by the NIHR Systematic Reviews Programme as project number 135560. ",

year = "2022",

month = jun,

day = "20",

language = "English",

publisher = "Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence",

}

TY - BOOK

T1 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy

AU - Boyers, Dwayne

AU - Cruickshank, Moira

AU - Scott, Neil

AU - Jacobsen, Elisabet

AU - Kumar, Sachin

AU - Imamura, Mari

AU - Manson, Paul

AU - Preston, Gavin

AU - Brazzelli, Miriam

N1 - Source of funding: This report was commissioned by the NIHR Systematic Reviews Programme as project number 135560.

PY - 2022/6/20

Y1 - 2022/6/20

N2 - Evidence Review Group report in support of NICE STA Programme.

AB - Evidence Review Group report in support of NICE STA Programme.

UR - https://www.nice.org.uk/guidance/ta895

M3 - Commissioned Report

BT - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy

PB - Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence

CY - London

ER -

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this